Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial

IMPORTANCE: Interleukin 13 (IL-13) is a central pathogenic mediator driving multiple features of atopic dermatitis (AD) pathophysiology. OBJECTIVE: To evaluate the efficacy and safety of lebrikizumab, a novel, high-affinity, monoclonal antibody targeting IL-13 that selectively prevents formation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Guttman-Yassky, Emma, Blauvelt, Andrew, Eichenfield, Lawrence F., Paller, Amy S., Armstrong, April W., Drew, Janice, Gopalan, Ramanan, Simpson, Eric L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/
https://www.ncbi.nlm.nih.gov/pubmed/32101256
http://dx.doi.org/10.1001/jamadermatol.2020.0079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/
https://www.ncbi.nlm.nih.gov/pubmed/32101256
http://dx.doi.org/10.1001/jamadermatol.2020.0079

Ejemplares similares